8-K: Silexion Therapeutics Announces 1-for-15 Reverse Share Split to Maintain Nasdaq Listing

Silexion Therapeutics Corp. announced a 1-for-15 reverse share split, effective July 28, 2025, to comply with Nasdaq's minimum bid price requirement and enhance its market position.

Summary

• Silexion Therapeutics Corp. will implement a 1-for-15 reverse share split of its ordinary shares.
• The reverse share split will become effective after market close on July 28, 2025.
• Trading on a split-adjusted basis will commence at market open on July 29, 2025, on the Nasdaq Capital Market under the existing ticker symbol SLXN.
• The par value of ordinary shares will increase proportionately from $0.0009 per share to $0.0135 per share.
• No fractional shares will be issued; any fractional share totals for DTC participants will be rounded up to the nearest whole share.
• The primary purpose of the reverse split is to enable the Company to regain and maintain compliance with Nasdaq's minimum bid price requirement (Nasdaq Listing Rule 5550(a)(2)).
• The adjustment is also expected to enhance Silexion's market position, address share price volatility, support strategic growth initiatives, and enable future equity financings.

Sentiment

Score: 6

Explanation: The announcement of a reverse stock split is generally a neutral to slightly negative event as it addresses a low share price, but the company frames it positively as a strategic move to maintain Nasdaq listing, enhance market position, and enable future growth and financing, coupled with positive updates on preclinical breakthroughs and pipeline development.

Positives

• The reverse share split is a proactive measure to maintain Nasdaq listing compliance, which is crucial for market visibility and access to capital.
• The company recently achieved preclinical breakthroughs with SIL-204, its next-generation siRNA candidate.
• Silexion has an expanded development strategy across multiple KRAS-driven cancers, indicating a broader therapeutic pipeline.
• The company's first-generation product, LODER, has shown promising results in a Phase 2 trial for non-resectable pancreatic cancer.
• The reverse split is designed to enhance capital markets position and support continued progress toward bringing potentially transformative therapies to patients.

Negatives

• The necessity of a reverse share split typically indicates a sustained low share price, which can be perceived negatively by investors.
• The reverse split itself does not fundamentally change the company's underlying value or operational performance.

Risks

• Silexion's ability to successfully complete preclinical studies and initiate clinical trials is uncertain.
• Future operations, financial position, projected costs, prospects, and plans are subject to various risks.
• The impact of the regulatory environment and compliance complexities could affect operations.
• Expectations regarding future partnerships or other relationships with third parties may not materialize.
• Silexion's future capital requirements and ability to obtain additional capital are uncertain.
• Maintaining the Nasdaq listing after the reverse split is not guaranteed and depends on sustained compliance.
• Other risks and uncertainties are set forth in the Company's Annual Report on Form 10-K for the year ended December 31, 2024, filed with the SEC on March 18, 2025.

Future Outlook

Silexion Therapeutics aims to advance its innovative RNAi therapeutics, including SIL-204, toward clinical trials for KRAS-driven cancers, with a focus on improving outcomes for patients with difficult-to-treat cancers. The reverse split is expected to enhance the company's capital markets position and support its strategic growth initiatives, including enabling future equity financings.

Management Comments

• "Our decision to implement this reverse share split reflects Silexion's unwavering commitment to maintaining our Nasdaq listing and strengthening our foundation for future growth."
• "Following our recent preclinical breakthroughs with SIL-204 and our expanded development strategy across multiple KRAS-driven cancers, I remain highly confident in our ability to advance our innovative RNAi therapeutics toward clinical trials and ultimately deliver meaningful value to both patients and shareholders."
• "This reverse split is designed to enhance our capital markets position, address share price volatility, and support our continued progress toward bringing potentially transformative therapies to patients with difficult-to-treat cancers."

Industry Context

Silexion Therapeutics operates in the highly competitive and innovative biotechnology sector, specifically focusing on RNA interference (RNAi) therapies for oncology. Their focus on KRAS-driven cancers addresses a significant unmet medical need, as KRAS mutations are common oncogenic drivers. The development of next-generation siRNA candidates like SIL204 positions them within the cutting-edge of targeted cancer therapies. The need for a reverse stock split is a common occurrence for smaller biotech companies seeking to maintain exchange compliance, reflecting the challenges of capital markets for early-stage drug developers.

Comparison to Industry Standards

• The document does not provide specific financial or operational metrics that allow for a direct comparison to industry-specific benchmarks or comparable companies like Amgen, Gilead Sciences, or other clinical-stage oncology biotechs in terms of revenue, R&D spend, or clinical trial success rates.
• The mention of LODER's promising results in a Phase 2 trial for non-resectable pancreatic cancer is a positive clinical milestone, but without specific data or comparison to other pancreatic cancer therapies (e.g., Abraxane, Gemzar), its relative performance cannot be assessed.
• Preclinical breakthroughs with SIL-204 for colorectal and lung cancer applications are noted, but these are early-stage developments and do not yet have industry-standard clinical trial data for comparison.

Stakeholder Impact

• Shareholders: The number of shares held will decrease by a 1-for-15 ratio, but the proportional ownership percentage will remain the same. Fractional shares will be rounded up for DTC participants. The split aims to maintain Nasdaq listing, which benefits shareholders by preserving liquidity and market access.
• Investors: The split is intended to make the stock more attractive to institutional investors by increasing the per-share price and potentially reducing volatility, and enabling future equity financings.
• Patients: The company's continued progress in developing RNAi therapies for KRAS-driven cancers, supported by the strategic move, could ultimately lead to new treatment options for difficult-to-treat cancers.

Next Steps

• The reverse share split will become effective after market close on July 28, 2025.
• Ordinary shares will begin trading on a reverse split-adjusted basis on the Nasdaq Capital Market at market open on July 29, 2025.
• Silexion aims to advance its innovative RNAi therapeutics toward clinical trials.
• The company will continue to push the boundaries of therapeutic innovation in oncology.

Key Dates

Recommendation

Keywords

Silexion Therapeutics, Reverse Share Split, NASDAQ Listing, Biotechnology, RNA interference, RNAi therapies, KRAS-driven cancers, Oncology, Clinical-stage, SIL-204, LODER, Pancreatic Cancer, Colorectal Cancer, Lung Cancer, Biopharma, SEC Filing, 8-K